yahoo_financeOriginal article
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
Phase 2positiveNEO100Positive
AI Analysis
Summary
NeOnc Technologies reported positive topline Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma.
Clinical Trial Data
Phase
2a
Primary Endpoint
Met
Outcome Details
Positive topline Phase 2a results
Importance:7/10
Sentiment:
0.80
Phase 2apositive dataintranasalgliomaoncology
Related Companies
Read the original article
Published by yahoo_finance on August 12, 2026 12:00 PM